# Junta clínica — PT-pseudo_d5ceb6b4204f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_d5ceb6b4204f",
  "pid": "PT-pseudo_d5ceb6b4204f",
  "task": 1,
  "psa": 4.1,
  "age": 72,
  "months": 1,
  "pirads": "4",
  "psad": 0.181,
  "psav": 0.77,
  "psap": 3.3,
  "vol": 22.65,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8003183,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "173 cm",
    "bmi": "30.1",
    "bp": "130/80 mmHg",
    "hr": "58 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2021)",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable."
    }
  ],
  "occupation": "retired bus driver",
  "marital": "Widowed",
  "living": "Lives in assisted-living facility",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Dermatology — actinic keratosis check",
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d5ceb6b4204f
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 72-year-old male
  - PSA: 4.1 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.181 ng/mL²
  - PSA velocity: 0.77 ng/mL/yr
  - Prior PSA: 3.3 ng/mL
  - Prostate volume: 22.65 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8003183 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.1 ng/mL. PI-RADS 4. PSAD 0.18. Prostate volume 23 mL. csPCa 0.80.

Vitals: weight 90 kg, height 173 cm, BMI 30.1, BP 130/80 mmHg, HR 58 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2021).

Chief complaint: Clinical reassessment prompted by a PSA increase to 4.1 ng/mL alongside a previously confirmed positive biopsy result.

History: A 72-year-old retired bus driver, widowed, entered the workup for a PSA elevation in mid-2023, a value that has now climbed to 4.1 ng/mL. He resides in an assisted-living facility situated over 90 minutes from the hospital, prompting a preference for telephone monitoring when clinically suitable. Despite his years, his lifestyle remains vigorous; he jogs 5 km three times each week and experiences only slight urinary bother, scoring a 7 on the IPSS. Tobacco use ceased entirely in 2021 after accumulating 10 pack-years, and he avoids alcohol. No comorbidities are present, and he takes no medications. Unrelated recent medical encounters include a dermatology visit for actinic keratosis monitoring and a completed six-session physiotherapy regimen addressing mechanical lower back pain. He maintains baseline functionality without systemic complaints.

Physical examination: DRE — texture: uniformly smooth; mobility: unrestricted; asymmetry: absent. The prostate appears symmetrically benign with no palpable nodules, confirming a normal digital rectal assessment. General inspection shows a well-nourished gentleman free of acute distress, maintaining stable vital signs and clear breath sounds. Abdominal palpation yields no masses or organomegaly, remaining entirely unremarkable.

Patient info: retired bus driver; Widowed; Lives in assisted-living facility.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; Physiotherapy — lower back, six sessions.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.69
  uncertainty  +/- 0.10 epistemic (95% band 0.49-0.89); among patients I cannot tell apart the outcome was 0.89 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 4, PSA 4.1, PSAD 0.181, age 72, DRE Normal -> BIOPSY (borderline). He wrote: "Borderline older patient, favorable intermediate risk disease with perineurial features. Low PSA (why was he biopsied in 2023 under non-elevated PSA?). While only one pr…"
  2. distance 1.04: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"
  3. distance 1.04: PI-RADS 4, PSA 5.2, PSAD 0.151, age 68, DRE Normal -> BIOPSY (uncertain). He wrote: "Again missing earlier ISUP grading and if the PIRADS 4 lesion is stabile or growing"

PRECEDENT: BIOPSY. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: age=important, fh=noted, psad=important, vol=noted, bx=important, comorbidity=important, psa=important, pirads=important, dre=important.
HOW SURE HE USUALLY IS: borderline.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI is mandated to confirm histological progression before a change in treatment strategy. A stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings and the PSA density threshold. The panel variables alone do not settle the indication, as the guideline requires assessment of the MRI status and PSA density. The precedent suggests that the decision hinges on the documented grade of the prior biopsy and surveillance history, which is a fact that the guideline makes decisive that no panel variable represents.

WHAT WE STILL NEED
The guideline requires the MRI status and PSA density to make a decision.
Prior biopsy status: Positive.
PI-RADS score: 4.
PSA density: 0.181 ng/mL².
The guideline requires the MRI status to determine if a repeat biopsy is warranted.
The documentation regarding the grade of the prior biopsy and surveillance history is needed to assess the risk.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the documented grade and surveillance status from the previous notes, as the panel variables are insufficient.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and hemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented Gleason or ISUP grade of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Multiparametric MRI of the Prostate | Date: 10 Jan 2025 | Facility: Amsterdam UMC (AMC campus)
What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study? The gland measures 22.65 mL in volume. T2-weighted sequences highlight an asymmetric focal hypointensity in the right mid-gland peripheral zone, spanning roughly 12 mm. There is no evidence of extraprostatic extension or seminal vesicle invasion. Comparison against an earlier study: new.

psa_trend
What is the serial PSA value trend (rising, flat, or falling)? The serial PSA value trend is rising, with values: "Jul 2023": "1.0", "Jan 2024": "1.2", "Jul 2024": "3.4", "Jan 2025": "4.1".

previous_notes
What is the management context, including the prior biopsy grade (Gleason/ISUP), number and dates of biopsy sessions, and surveillance protocol status? Management context: "Consultation focused on tracking the ascending PSA trajectory. An earlier reading from July 2023 recorded 1.7 ng/mL, followed by a January 2024 measurement of 2.2 ng/mL. The individual notes stable, mild lower urinary tract complaints while continuing a consistent running schedule. Laboratory panels were ordered to track the progression, and a specialist urology referral was processed given the steady increase and the history of a previously positive biopsy." Prior biopsy grade: not recorded. Number and dates of biopsy sessions: not recorded. Surveillance protocol status: not recorded.

laboratory_results
What are the full panel results, including free-PSA fraction, renal function, and hemoglobin? PSA: "4.1 ng/mL" on "30 Nov 2024" with flag "H". Free PSA: "0.48 ng/mL" on "30 Nov 2024" with flag "". %Free PSA: "12%" on "30 Nov 2024" with flag "L". Creatinine: "81 umol/L" on "30 Nov 2024" with flag "". eGFR: ">60 mL/min/1.73m2" on "30 Nov 2024" with flag "". Haemoglobin: "14.3 g/dL" on "30 Nov 2024" with flag "".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes already mentioned the history of a previously positive biopsy, and the task description stated that the pathology report should not be pulled up.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of 4 from the mpMRI report.
Rising PSA trend from 1.0 ng/mL in Jul 2023 to 4.1 ng/mL in Jan 2025.

Findings that argue AGAINST sampling this patient now:
Prior biopsy result is positive, and the previous notes do not specify the prior biopsy grade or surveillance status.

WHERE THIS LEANS
The documents suggest a need for further clarification on the prior biopsy outcome and surveillance plan, leaning towards needing more information before a definitive decision.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.10 ng/mL over 4 points spanning 18 months; velocity +2.30 ng/mL per year; doubling time about 8 months.
PROJECTION at 6 months: 5.5 ng/mL, conformal 95% band 1.6-19.3.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.66
  uncertainty  +/- 0.14 epistemic (95% band 0.39-0.93), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.69  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.66  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (identical panel in the series)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: borderline. Weights it expects: age=important, fh=noted, psad=important, vol=noted, bx=important, comorbidity=important, psa=important, pirads=important, dre=important.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions. Specifically, the previous_notes state that the prior biopsy grade and surveillance status are "not recorded."

ALIGNMENT WITH THE PANEL
The Panel Protocol concludes with BIOPSY based on an identical precedent in the labelled series, which is supported by the EXPERT-LIBRARY. However, this conclusion rests on the finding that the "documented prior grade in the opened documents: none recorded," which directly addresses the missing information required by the guideline.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented Gleason or ISUP grade of the prior biopsy? This question remains unanswered as the previous_notes explicitly state this information is not recorded.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? This question also remains unanswered as the previous_notes state this status is not recorded.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables for the EAU guideline are the MRI status and PSA density. The MRI report shows a PI-RADS 4 lesion, and the PSA density is 0.181 ng/mL². These factors suggest a need for further assessment, as per the EAU guideline's dependence on MRI status and PSA density thresholds.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade and surveillance status is missing from the retrieved documents, the record is not yet in a state to be definitively decided according to the guideline. Therefore, the decision cannot be made yet.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

A biopsy is recommended because the patient presents with a PI-RADS 4 lesion and a rising PSA trend from 1.0 ng/mL to 4.1 ng/mL, which suggests the disease is progressing. Although the prior biopsy result grade and surveillance status were not recorded, the combination of the PI-RADS 4 score and the rising PSA trajectory supports further histological clarification. The room converged on this decision despite the missing documentation regarding the prior biopsy grade.

What carried weight: age=important, psad=important, vol=noted, bx=important, comorbidity=important, psa=important, pirads=important, dre=important
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
